ArticleWorld journal of gastrointestinal oncology2025
Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter arterial chemoembolization (TACE) combined with lenvatinib is an important modality for the treatment of unresectable hepatocellular carcinoma (HCC). To date, no prognostic analysis exists for clinical predictive models of TACE combined with lenvatinib in treating advanced unresectable HCC. A model was constructed through meta-analysis, and its validation was further enhanced by the collection of external clinical data, thereby providing guidance for clinical practice.
aimTo identify risk factors for unresectable HCC following TACE plus lenvatinib therapy and to construct a clinical prediction model.
methodsWe searched PubMed, Web of Science, EMBASE, and Cochrane Library databases for studies on TACE plus lenvatinib for unresectable HCC. Risk factors from the meta-analysis and sensitivity analyses were used to construct a prediction model. The validation set included clinical data from 106 eligible patients at the Affiliated Hospital of North Sichuan Medical College collected by June 1, 2023.
resultsThis study included 43 group studies involving 5070 patients. Tumor number, microvascular invasion, Eastern Cooperative Oncology Group performance status, Child-Pugh stage, Barcelona Clinic Liver Cancer stage, extrahepatic metastases, alpha-fetoprotein level, and hepatitis B virus status were risk factors for overall survival and progression-free survival, while triple therapy was a protective factor for both. In the validation set, the overall survival prediction model had area under the curve values of 0.616, 0.643, and 0.706 at 1 year, 2 years, and 3 years, respectively, and the progression-free survival model had area under the curve values of 0.702, 0.696, and 0.670 at the corresponding time points, demonstrating good model performance. Calibration curves, Kaplan-Meier survival analysis, and decision curves further validated the efficacy of the model.
conclusionModels based on nine variables from 43 group studies predicted the efficacy of TACE plus lenvatinib in unresectable HCC, supporting evidence-based clinical decisions and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.